Skip to main content
Sister Publication Links
  • ESG: THE NEW IMPERATIVE
Subscribe
  • My Account
  • Login
  • Subscribe
  • News
    • Current News
    • COVID-19
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Transformation
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Digital Health
  • Insights
    • ACA 10 Years After
    • Best Practices
    • Special Reports
    • Innovations
  • Data/Lists
    • Rankings/Lists
    • Interactive Databases
    • Data Points
  • Op-Ed
    • Bold Moves
    • Breaking Bias
    • Commentaries
    • Letters
    • Vital Signs Blog
    • From the Editor
  • Awards
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top 25 Innovators
    • Diversity in Healthcare
    • Women in Healthcare
    • - Luminaries
    • - Top 25 Diversity Leaders
    • - Leaders to Watch
    • - Luminaries
    • - Top 25 Women Leaders
    • - Women to Watch
  • Events
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Custom Media Event: ESG Summit
    • Transformation Summit
    • Women Leaders in Healthcare Conference
    • Social Determinants of Health Symposium
    • Leadership Symposium
    • Health Care Hall of Fame Gala
    • Top 25 Women Leaders Gala
    • Best Places to Work Awards Gala
    • Top 25 Diversity Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Supply Chain Revenue Cycle
    • - Hospital at Home
    • - Workplace of the Future
    • - Strategic Marketing
    • - Virtual Health
  • Listen
    • Podcast - Next Up
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Video Series - The Check Up
    • Sponsored Video Series - One on One
  • MORE +
    • Advertise
    • Media Kit
    • Newsletters
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Law & Regulation
May 01, 2022 04:00 AM

University Hospitals doc's ureteral stent secures FDA clearance

Crain's Cleveland Business
Lydia Coutré
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print
    Relief with box_i.jpg
    Contributed
    The Relief Stent — a new urinary stent invented by Dr. Lee Ponsky, UH Chair of the Department of Urology, in collaboration with Dean Secrest — recently secured its FDA 510k clearance. It offers the potential to reduce side effects associated with current ureteral stents on the market, including urine reflux, flank pain and bladder spasms.

    After years of hearing from patients how bothersome — and sometimes painful — ureteral stents are, Dr. Lee Ponsky, chair of the Department of Urology at University Hospitals, experienced the discomfort himself. Twice.

    These stents help ease the flow of urine along the ureter, which connects the kidney to the bladder. They help prevent kidney damage caused by kidney stones, strictures or swelling of the ureter. While some patients don't have any pain, Ponsky said upwards of 60% to 80% of patients with these ureteral stents currently available will have problems or complaints, including urine reflux, flank pain and bladder spasms. These can lead to additional medical attention and sometimes the need for replacements.

    About a decade ago, he began redesigning the stent, creating what he's dubbed the Relief Stent, which in March secured its 510k clearance from the U.S. Food and Drug Administration and allowed it to be marketed in the United States for patients suffering from kidney stones and other issues causing difficulty draining the kidney.

    "I always had an interest in ways that we can improve some of the discomfort that a patient has, but there's nothing more of a motivator than being a patient yourself," said Ponsky, also a master clinician in urologic oncology, and the Leo & Charlotte Goldberg chair in Advanced Surgical Therapies at UH.

    The Relief Stent's design offers the potential to reduce some of the side effects associated with existing ureteral stents, according to UH. It allows the ureteral orifice to close naturally to reduce reflux and also avoids irritating the floor of the bladder, which causes pain and bladder spasms, Ponsky said.

    To help advance the device, Ponsky founded the Ureteral Stent Co. as a subsidiary of Cleveland-based Walden Medical Companies.

    Walden Medical seeded Ureteral Stent with $200,000 in founding shares that then converted into a series A financing that ultimately raised a total of $2 million in March 2020, said Mike Bunker, president of both Walden Medical and Ureteral Stent. Right now, they've not decided to raise a full series B, but to provide resources through 2023, they raised $1.5 million internally through a convertible note round from existing investors, Bunker said.

    UH Ventures, the commercialization arm of University Hospitals, invested in the company and helped Ponsky also obtain funding from Ohio Third Frontier's Technology Validation and Start Fund, which aims to accelerate the translation of technologies through Ohio startup companies. ProMedica Innovations — the innovation arm of ProMedica — invested in Ureteral Stent Company, as well, after consulting urologists in the health system and hearing existing ureteral stents were a pain point for patients, said Zach Philipp, investment associate for ProMedica Innovations.

    "The feedback was resounding that this is something that would be an improvement compared to what's currently on the market," he said. "And so not only were we able to validate it with shared due diligence with UH, when we went through this process, but we also validated it internally and that's really what got our attention."

    UH Ventures has had co-hospital system investors on most of its deals since it launched in 2017, said Neil Wyant, vice president of investments and commercialization at UH Ventures.

    Download Modern Healthcare’s app to stay informed when industry news breaks.

    An early-stage company getting multiple hospital systems using and investing in its product helps it gain credibility much faster, Wyant said.

    Dr. Kyle Scarberry, a reconstructive urologist at UH, is the principal investigator of an ongoing Relief Stent study looking at safety that aims to enroll 30 patients.

    Bunker said down the road, the Relief Stent "really belongs in the hands of a urology company that has a full suite of products," such as devices to retrieve kidney stones or ultrasound machines to break them up. He said the team plans to consult notable stone management physicians to demonstrate they have the right product design.

    "The first thing out of the gate is really, let's get some real-world feedback on the product before we say that it's ready for, you know, a huge commercial launch and investment that that would entail," Bunker said.

    Bunker said he and Ponsky last met with some of these experts in 2019 at the American Urological Association meeting and essentially used the insights they gained there to create a blueprint for their work in the past couple of years to take the product through this latest milestone. They've designed and are currently vetting a study to prove the Relief Stent is "superior in patient comfort, healthcare economics and lowering reflux."

    "The design is fairly obvious, but we've not proven that," Bunker said. "We only can prove that we can drain urine from the kidney to the bladder."

    Though they haven't proven those claims, it's an option for a post-market study in order to sell the benefits of the stent, Bunker said. Other decisions ahead include remaining independent, partnering with another entity or even having an option to acquire the company.

    "There's lots of variables that could come in here," he said, "and we'll know a lot more in the next few months."

    This story first appeared in our sister publication, Crain's Cleveland Business.

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    Pfizer says 3 COVID shots protect children under 5
    Pfizer says 3 COVID shots protect children under 5
    kids covid vaccine
    CDC urges Pfizer booster for children ages 5 to 11
    Sponsored Content
    Daily Dose Newsletter: Sign up to receive a late afternoon weekday roundup of that day’s breaking news and developments in healthcare.
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2022. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • COVID-19
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Digital Health
    • Insights
      • ACA 10 Years After
      • Best Practices
      • Special Reports
      • Innovations
    • Data/Lists
      • Rankings/Lists
      • Interactive Databases
      • Data Points
    • Op-Ed
      • Bold Moves
      • Breaking Bias
      • Commentaries
      • Letters
      • Vital Signs Blog
      • From the Editor
    • Awards
      • Nominate/Eligibility
      • 100 Most Influential People
      • 50 Most Influential Clinical Executives
      • Best Places to Work in Healthcare
      • Excellence in Governance
      • Health Care Hall of Fame
      • Healthcare Marketing Impact Awards
      • Top 25 Emerging Leaders
      • Top 25 Innovators
      • Diversity in Healthcare
        • - Luminaries
        • - Top 25 Diversity Leaders
        • - Leaders to Watch
      • Women in Healthcare
        • - Luminaries
        • - Top 25 Women Leaders
        • - Women to Watch
    • Events
      • Conferences
        • Transformation Summit
        • Women Leaders in Healthcare Conference
        • Social Determinants of Health Symposium
        • Leadership Symposium
      • Galas
        • Health Care Hall of Fame Gala
        • Top 25 Women Leaders Gala
        • Best Places to Work Awards Gala
        • Top 25 Diversity Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Supply Chain Revenue Cycle
        • - Hospital at Home
        • - Workplace of the Future
        • - Strategic Marketing
        • - Virtual Health
      • Webinars
      • Custom Media Event: ESG Summit
    • Listen
      • Podcast - Next Up
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Video Series - The Check Up
      • Sponsored Video Series - One on One
    • MORE +
      • Advertise
      • Media Kit
      • Newsletters
      • Jobs
      • People on the Move
      • Reprints & Licensing